Product Description
Fenoldopam is used primarily for the lowering of blood pressure during episodes of severe hypertension. Fenoldopam has a unique mechanism of action compared to other antihypertensive medications: it is a dopamine (D1) receptor agonist that results in decreased peripheral vascular resistance primarily in renal capillary beds, thus promoting increased renal blood flow, natriuresis, and diuresis. Fenoldopam has minimal adrenergic effects. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK526058/)
Mechanisms of Action: D1 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Greece | Ireland | Italy | United States
Approved Indications: Hypertension | Hypertension, Malignant
Known Adverse Events: Hypotension | Headache | Flushing
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|